Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)

This study is testing whether adding an immunotherapy drug called toripalimab (a PD-1 blocker) to standard chemotherapy before surgery helps shrink tumors in women with a hormone-receptor positive, HER2-negative breast cancer that also shows signs of immune activity (PD-L1 positive). **You may be eligible if...** - You are a woman between 18 and 75 years old - You have been diagnosed with HR+/HER2- invasive breast cancer with a tumor larger than 1 cm - Your cancer tests positive for PD-L1 - You have not yet received chemotherapy - Your overall health and organ function are within acceptable ranges - Your heart's pumping function is greater than 55% **You may NOT be eligible if...** - You have another active cancer - You have significant heart, liver, or kidney problems - You are pregnant or planning to become pregnant - You have autoimmune disease or a history of serious immune-related side effects Talk to your doctor to see if this trial is right for you.